Glaxo abacavir ("1592") compassionate use program for pediatric AIDS to be launched in June.
Executive Summary
GLAXO ABACAVIR EXPANDED ACCESS PROGRAM IN PEDIATRIC AIDS TO BEGIN IN JUNE, the company told HIV/ AIDS groups in a recent letter. A reverse transcriptase inhibitor, abacavir (1592U89) is in Phase III trials, with an NDA filing expected in 1998. In July, Glaxo Wellcome plans to launch two additional compassionate use programs: for people with severe AIDS Dementia Complex (ADC) and for the adult AIDS population. A broader program is planned for early 1998. The initiatives will run concurrently with controlled clinical trials, the letter states.